Vector BioPharma and the Instituto de Biologia Experimental e Tecnológica (iBET) have agreed a multi-phase collaboration to advance the technical development of Vector’s gene delivery platform. Vector BioPharma’s gene delivery platform combines high-capacity virus-like particles with exogenous, high-avidity adapter proteins. Lorenz Mayr, CEO at Vector BioPharma, said: “Collaboration with industry-leading R&D institutions and researchers in […]
